Painkiller-blood thinner combo under scrutiny in cancer patients

NCT ID NCT07384013

Recruiting now Knowledge-focused Sponsor: Rambam Health Care Campus Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at how metamizole (Optalgin), a common painkiller, changes the levels of blood thinners (apixaban or rivaroxaban) in cancer patients. Researchers will measure drug concentrations at several time points in 30 adults. The goal is to understand if metamizole interferes with these anticoagulants, which could affect bleeding or clotting risks.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: metamizole (Optalgin)
What this could lead to: If successful, this could help doctors safely combine metamizole with blood thinners in cancer patients, reducing bleeding or clotting risks.
What could go wrong: This is a small, early-stage observational study with only 30 participants, so results may not apply broadly. It does not test a new treatment, only measures drug interactions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COAGULATION DEFECT are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

agnosia blood coagulation disease cancer neoplasm vascular hemostatic disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

COAGULATION DEFECT ONCOLOGIC DISEASES PAIN MANAGEMENT

Contacts and locations

Locations

Rambam Health Care Campus
RECRUITING

Haifa, 31096, Israel

More trials for these conditions

Other studies related to the condition(s) this trial covers.